Dr Martin Kaiser is a Clinician Scientist and Honorary Consultant Haematologist working on improving outcomes of multiple myeloma, a relapsing-remitting bone marrow cancer.
He attended medical school and obtained an MD degree in myeloma research at the University of Aachen (RWTH), Germany and completed his specialist training at Charité University Hospital in Berlin, Germany. In 2011, he joined The Institute of Cancer Research, London, and has headed the Myeloma Group, part of the Division of Molecular Pathology, since 2014.
His research focuses on integrated molecular profiling for biomarker and target identification for stratified medicine in multiple myeloma. Specific areas of activity are genomic and epigenomic molecular profiling of high-risk myeloma and epigenetically driven disease, including the t(4;14) sub-group. Through collaborations with the ICR’s Division of Cancer Therapeutics, external partners like the Structural Genomics Consortium (SGC) in Oxford and industry, the group has access to novel and innovative tool compounds and candidate drugs for pre-clinical and clinical drug development in myeloma.
Dr Kaiser heads trial-specific myeloma biobanking for multi-centric UK NCRI phase III trials and for phase I/II studies in the Myeloma UK Clinical Trials Network. He is Chief Investigator of academically led trials with a particular focus on molecular treatment stratification and biomarker discovery. In collaboration with Dr Christina Messiou (The Royal Marsden, Radiology), Dr Kaiser is investigating innovative imaging methods for improved patient care, in particular diffusion-weighted whole body MRI.
He is member of the UK National Cancer Research Institute Clinical Studies Groups Myeloma sub-group and Lead for the Genomics England Clinical Interpretation Partnership Haematology sub-group for myeloma. He works closely with the patient charity Myeloma UK and is a member of the Myeloma UK Research Advisory Group.
In July 2018, Martin became the first Jacquelin Forbes-Nixon Research Fellow. This was announced by the David Forbes-Nixon Charitable Foundation who are funding research to find a cure for myeloma. The establishment of the Fellowship marks a significant milestone in working towards achieving this goal.
Under the Fellowship, Dr Kaiser will undertake a programme of work to identify and characterise the genetic changes responsible for the progression of myeloma and why it becomes resistant to treatment.